NOT-DA-21-083: Notice of clarification in RFA-DA-22-022, " Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional)"

Notice of clarification in RFA-DA-22-022, " Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional)"

Notice Number:

NOT-DA-21-083

Key Dates

Release Date:

September 21, 2021

Related Announcements

RFA-DA-22-022 - Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3, Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This notice clarifies the "Award Budget" in Section II. Award Information of RFA-DA-22-022. UG3 application budgets are limited to $500k in direct costs per year. UH3 phase application budgets should not exceed $1 million in direct costs per year. Application budgets should reflect the actual needs of the project.

Inquiries

Please direct all inquiries to:

Aidan Hampson, Ph.D.
National Institute on Drug Abuse
Telephone: 301-827-5925
Email: [email protected]